WO2004010994A1 - インドメタシン外用剤 - Google Patents
インドメタシン外用剤 Download PDFInfo
- Publication number
- WO2004010994A1 WO2004010994A1 PCT/JP2003/009273 JP0309273W WO2004010994A1 WO 2004010994 A1 WO2004010994 A1 WO 2004010994A1 JP 0309273 W JP0309273 W JP 0309273W WO 2004010994 A1 WO2004010994 A1 WO 2004010994A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- added
- indomethacin
- weight
- preparation
- monostearate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to an external preparation for indomethacin which is excellent in use feeling and absorbability, and which can maintain a stable state without separation of the preparation over time.
- dosage forms such as gels, creams, liquids and cataplasms are commercially available, and each dosage form has unique characteristics.
- a gel contains a large amount of alcohol, so it has good solubility of indomethacin and excellent absorption from the skin.
- it is a phenomenon peculiar to the gel. Phenomenon that accumulates when applied), resulting in poor usability.
- creams have a good feeling of use without stickiness after use because they contain a sufficient amount of oil, but because of poor solubility of indomethacin, absorption from the skin is worse than that of gels. ,.
- creams usually contain surfactants to suppress the separation of the oily and aqueous layers, but if a large amount of alcohol is added to the creams, the alcohol interferes with the emulsification of the surfactants. As a result, the preparation is separated into an oil layer and an aqueous layer over time. Even if a gelling agent is added to such an extent that no bleeding occurs, it is difficult to suppress the separation of the preparation over time.
- an object of the present invention is to provide an external preparation for indomethacin which is excellent in use feeling and absorbability, and which can maintain a stable state without separation of the preparation over time.
- an amount of alcohol that dissolves indomethacin an amount of oil that can provide a good feeling of use is blended, and there is no separation between the oil layer and the water layer, and the stability over time is excellent.
- Another object of the present invention is to provide an external preparation for indomethacin.
- the alcohol 2 5-5 0 weight 0/0 can sufficiently dissolve indomethacin in to the formulation, after ® Les generation and use of use
- two or more components 0. 0 1 to 0 weight 0/0 by blending, found that over time separation of the formulation is inhibited, thereby completed the present invention.
- the present invention is as follows.
- indomethacin from 0.1 to 3 wt 0/0, the alcohol 2 5-5 0 weight 0/0, gelling agent 0.0 1-5% by weight, oil 5-3 0 wt%, water 2 0-5 0% by weight and one or more components selected from glycerin monostearate, sorbitan monostearate, stearyl alcohol, and polyethylene dalichol monostearate in an amount of 0.01 to 10% by weight.
- the indomethacin external preparation of the present invention comprises 0.1 to 3% by weight of indomethacin and 25 to 50% by weight of alcohol. /. , Gelling agent 0.0 1-5% by weight, oil content 5-30% by weight, water
- glyceryl monostearate 20 to 50% by weight, and 0.01 to 10% by weight of one or more components selected from glyceryl monostearate, sorbitan monostearate, stearyl alcohol and polyethylene glycol monostearate I do.
- the indomethacin external preparation of the present invention is excellent in use feeling and absorbability, and can keep the stability over time of the preparation without causing separation of an oil layer and an aqueous layer.
- the content of indomethacin in the present invention is usually 0.1 to 3% by weight, preferably 0.2 to 2% by weight, particularly preferably 0.5 to 1.5% by weight based on the total amount of the preparation.
- the alcohol in the present invention is preferably a lower alcohol, more preferably an anolecol having 1 to 3 carbon atoms.
- a lower alcohol more preferably an anolecol having 1 to 3 carbon atoms.
- methanol, ethanol, isopropanol, n-propanol and the like can be exemplified. Among them, isopropanol is more preferable.
- the content of the alcohol is usually 2 5-5 0 weight 0/0 for the total formulation, preferably
- It is preferably from 30 to 50% by weight, particularly preferably from 30 to 40% by weight. If it is less than 25% by weight, absorption of indomethacin is poor due to insufficient dissolution of the indomethacin, and if it exceeds 50% by weight, skin irritation is caused, and it is not preferable because power products are separated over time.
- Examples of the genorizing agent in the present invention include, for example, ataline oleic acid-based polymers such as carboxyvull polymer, cellulose-based polymers such as hydroxypropylmethylcellulose and ethynolecellulose, and polyvinyl alcohol. .
- the content of Genore agent is usually 0. 0 1-5% by weight relative to the whole preparation, preferably from 0.5 to 5% by weight, particularly preferably 0.5 to 2.5 wt 0/0.
- oil component in the present invention examples include hydrocarbons such as squalane, liquid paraffin and the like, and esters such as isopropyl myristate, diisopropyl adipate and octyldodecyl myristate.
- the content of oil is preferably usually 5-3 0% by weight relative to the whole preparation, more preferred properly is 7 to 3 0 wt 0/0, and particularly preferably 7-2 0 weight 0/0.
- Glycerin monostearate, sonolebitan monostearate The content of one or more components selected from stearyl alcohol and polyethylene glycol monostearate is usually 0.01 to 10% by weight, preferably 0.05 to 5% by weight, particularly 0.05 to 5% by weight, based on the total amount of the preparation. Preferably it is 0.1 to 5% by weight. If the amount is less than 0.01% by weight, the separation of the preparation over time cannot be suppressed. If the amount exceeds 10% by weight, the consistency of the preparation increases and the composition becomes hard, which is unfavorable because of poor usability.
- the melting points of all of these components are usually 40. C or higher, preferably 50 ° C or higher. If the melting point is lower than 40 ° C, it is not preferable because separation of the preparation over time cannot be suppressed.
- glyceryl monostearate used in the present invention is a mixture of glyceryl monostearate and other fatty acid esters of glycerin and is generally used as a base.
- -KKOR MGS-A, MGS-B, MGS-F20, MGS-F40 manufactured by Nikko Chemicals
- Leodol MS-165, Leodor MS-60 manufactured by Kao
- Kao Kao
- the sorbitan monostearate used in the present invention is a monostearate obtained by esterifying the hydroxyl group of anhydrous sorbitol with stearic acid and is generally used as a base.
- Nikkor SS-10, SS-10M manufactured by Nikko Chemicals
- Sorgen 50, Solman S-300 manufactured by Takeda Pharmaceutical are commercially available.
- the stearyl alcohol used in the present invention includes, for example, Calcol (manufactured by Kao), Nikkor deodorized stearyl alcohol (manufactured by Nikko Chemicals), Lanette 18 (manufactured by Henkel Japan), Conol 30S, Connol 3 OSS, Connol 3OF (New) Nippon Rika), NAA-45, NAA-46 (manufactured by Nippon Yushi) and the like are commercially available.
- polyethylene glycol monostearate used in the present invention is a substance obtained by adding ethylene oxide to stearic acid or a substance obtained by esterifying polyethylene glycol with stearic acid, and is generally used as a base.
- polyethylene glycol monostearate manufactured by Nikko Chemicals
- Nikko Chemicals is commercially available.
- the content of water in the present invention is usually 20 to 50 weight 0/0 for the whole preparation, preferred It is preferably from 30 to 50% by weight, particularly preferably from 40 to 50% by weight.
- the indomethacin external preparation of the present invention can contain various optional components as desired. For example, it may contain a neutralizing agent, a preservative, a stabilizer, a wetting agent, and the like.
- examples of the neutralizing agent include organic acids such as citric acid, phosphoric acid, tartaric acid, and lactic acid, inorganic acids such as hydrochloric acid, alkali hydroxides such as sodium hydroxide, triethanolamine, diethanolamine, and diisopropanol. Amines such as amines.
- preservative examples include baloxybenzoic acid esters, benzalcomium chloride and the like.
- examples of the stabilizer include sodium sulfite, sodium hydrogen sulfite, dibutylhydroxytoluene, butylhydroxysol, and edetic acid.
- examples of the wetting agent include glycerin, ethylene glycol, propylene glycol, and the like. Or polyhydric alcohols such as 1,3-butylene glycolone, isopropylene glycol, and polyethylene glycol.
- the pH of the external preparation of the present invention is usually pH: to 8, preferably pH 5 to 7, from the viewpoints of stability of indomethacin and skin irritation.
- the method for producing the external preparation of indomethacin of the present invention can be produced by a usual method.
- one or two or more kinds selected from glycerin monostearate, sorbitan monostearate, stearyl alcohol and polyethylene glycol monostearate can be used.
- step (3) 1 g of a 1% ETDA ⁇ 2NA aqueous solution and 2 g of a 2% aqueous sodium bisulfite solution were added to step (3), and mixed well.
- step (4) Add 0.8 g of diisopropanolamine to 5.2 g of water, dissolve with stirring, add to step (4), disperse well with cooling, and obtain a pale yellow-white gel cream formulation .
- step (2) 1 g of indomethacin, 3 g of L-menthol, and 401 g of polyethylene glycol were added to 36 g of isopropanol and dissolved by stirring. Then, the mixture was added to step (2), mixed well, and uniformly dispersed.
- step (3) 1 g of a 1% aqueous solution of D A ⁇ 2NA and 2 g of a 2% aqueous sodium bisulfite solution were added to step (3), and mixed well.
- step (3) 1 g of a 1% ETDA ⁇ 2NA aqueous solution and 2 g of a 2% aqueous sodium bisulfite solution were added to step (3), and mixed well.
- step (2) (3) 1 g of indomethacin, 3 g of L-menthol, and 400 lg of polyethylene glycol were added to 36 g of isopropanol and dissolved by stirring. Then, the mixture was added to step (2), mixed well, and uniformly dispersed.
- step (2) 1 g of indomethacin, 3 g of L-menthol and 400 g of polyethylene glycol were added to 36 g of isopropanol and dissolved by stirring, and then added to step (2), mixed well, and uniformly dispersed. -
- step (2) (3) 1 g of indomethacin, 3 g of L-menthol and 400 g of polyethylene glycol were added to 36 g of isopropanol and dissolved by stirring, and then added to step (2), mixed well, and dispersed uniformly.
- step (1) Disperse 2 g of Rubixibier polymer and 0.5 g of hydroxypropyl methylcellulose 2910 in 37.5 g of hot water at about 70 ° C, add to step (1) and mix well. And emulsified.
- step (3) 1 g of indomethacin, 3 g of L-menthol and 400 g of polyethylene glycol were added to 36 g of isopropanol, and the mixture was stirred and dissolved. The mixture was added to step (2), mixed well, and uniformly dispersed.
- step (2) 1 g of indomethacin, 3 g of L-menthenol and 400 g of polyethylenedaricol were added to 36 g of isopropanol and dissolved by stirring. Then, the mixture was added to step (2), mixed well, and uniformly dispersed.
- step (3) 1 g of 1% ETDA-2NA aqueous solution and 2 ° /. 2 g of aqueous sodium bisulfite solution was added to step (3) and mixed well.
- step (5) 0.8 g of disopropanolamine was added to 5.2 g of water, and the mixture was stirred and dissolved. The mixture was added to step (4) and dispersed well with cooling to obtain a pale yellow-white gel cream formulation. .
- step (2) (3) 1 g of indomethacin, 3 g of L-menthol, and 400 g of polyethylene glycol were added to 36 g of isopropanol and dissolved by stirring. Then, the mixture was added to step (2), mixed well, and uniformly dispersed.
- step (2) 1 g of indomethacin, 3 g of L-menthenol and 400 g of polyethylene glycol were added to 36 g of isopropanol and dissolved by stirring. Then, the mixture was added to step (2), mixed well, and uniformly dispersed.
- ETDA2N a 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 Sodium bisulfite 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 diisoprono-noreamine 0.8 0.8 0.8 0.8 0.5 0.8 1.0 0.8 0.8 1.0 water 44,2 45.7 44.2 44.2 43.0 46.2 45.5 44.2 44.2 43.5 Glycerin monostearate 2 3.5
- Table 2 shows the evaluation results of the stickiness
- Table 3 shows the evaluation results of the stickiness
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003281770A AU2003281770A1 (en) | 2002-07-29 | 2003-07-22 | Indometacin preparation for external use |
AT03741534T ATE485041T1 (de) | 2002-07-29 | 2003-07-22 | Indomethacin-präparat zur topischen anwendung |
US10/521,958 US7553865B2 (en) | 2002-07-29 | 2003-07-22 | Indomethacin external preparation |
DE60334630T DE60334630D1 (de) | 2002-07-29 | 2003-07-22 | Indomethacin-präparat zur topischen anwendung |
EP03741534A EP1541144B8 (en) | 2002-07-29 | 2003-07-22 | Indomethacin external preparation |
JP2004524120A JP4494202B2 (ja) | 2002-07-29 | 2003-07-22 | インドメタシン外用剤 |
HK05110853.0A HK1076256A1 (en) | 2002-07-29 | 2005-11-29 | Indometacin external preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002219315 | 2002-07-29 | ||
JP2002-219315 | 2002-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004010994A1 true WO2004010994A1 (ja) | 2004-02-05 |
Family
ID=31184731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/009273 WO2004010994A1 (ja) | 2002-07-29 | 2003-07-22 | インドメタシン外用剤 |
Country Status (14)
Country | Link |
---|---|
US (1) | US7553865B2 (ja) |
EP (1) | EP1541144B8 (ja) |
JP (2) | JP4494202B2 (ja) |
KR (1) | KR100996086B1 (ja) |
CN (1) | CN100438869C (ja) |
AT (1) | ATE485041T1 (ja) |
AU (1) | AU2003281770A1 (ja) |
DE (1) | DE60334630D1 (ja) |
ES (1) | ES2357229T3 (ja) |
HK (1) | HK1076256A1 (ja) |
MY (1) | MY141808A (ja) |
PT (1) | PT1541144E (ja) |
TW (1) | TWI299269B (ja) |
WO (1) | WO2004010994A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5011118B2 (ja) * | 2005-10-17 | 2012-08-29 | 興和株式会社 | インドメタシンを含有する外用液剤 |
US9012477B2 (en) * | 2009-01-06 | 2015-04-21 | Nuvo Research Inc. | Method of treating neuropathic pain |
CA2822220C (en) * | 2010-01-14 | 2016-10-25 | Nuvo Research Inc. | Solid-forming local anesthetic formulations for pain control |
CN105663030A (zh) * | 2012-06-29 | 2016-06-15 | 生春堂制药工业股份有限公司 | 水凝胶组成物及由其所组成的敷剂 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57126414A (en) | 1981-01-28 | 1982-08-06 | Sumitomo Chem Co Ltd | Ointment |
JPS58185514A (ja) | 1982-04-22 | 1983-10-29 | Hisamitsu Pharmaceut Co Inc | 新規な局所用消炎鎮痛ゲル状クリ−ム剤 |
JPS59227818A (ja) | 1983-06-09 | 1984-12-21 | Mitsubishi Chem Ind Ltd | ゲル状軟膏剤 |
JPS6261918A (ja) * | 1985-09-12 | 1987-03-18 | Sumitomo Pharmaceut Co Ltd | 吸収の良好な外用剤 |
JPH01279831A (ja) | 1988-04-30 | 1989-11-10 | Doujin Iyaku Kako Kk | インドメタシン軟膏剤 |
JPH05271075A (ja) * | 1992-03-26 | 1993-10-19 | Taisho Pharmaceut Co Ltd | 消炎鎮痛クリーム製剤 |
JPH10182458A (ja) * | 1996-12-26 | 1998-07-07 | Taisho Pharmaceut Co Ltd | インドメタシン含有外用剤組成物 |
JP2001354548A (ja) * | 2000-06-09 | 2001-12-25 | Shiseido Co Ltd | 乳化組成物 |
JP2003095985A (ja) * | 2001-09-26 | 2003-04-03 | Lion Corp | 血行促進組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2023000B (en) * | 1978-06-17 | 1982-10-13 | Kowa Co | Antinflammatory analgesic gelled ointments |
JPS5798209A (en) * | 1980-12-09 | 1982-06-18 | Kowa Co | Remedy for dermatopathy for external use |
JPS5829706A (ja) * | 1981-08-14 | 1983-02-22 | Toko Yakuhin Kogyo Kk | 消炎鎮痛外用剤 |
JPS58189115A (ja) * | 1982-04-30 | 1983-11-04 | Kowa Co | 外用剤 |
JPS61200907A (ja) | 1985-03-04 | 1986-09-05 | Taisho Pharmaceut Co Ltd | 坐剤 |
JPH05331066A (ja) * | 1992-05-25 | 1993-12-14 | Toko Yakuhin Kogyo Kk | 尋常性ざ瘡治療用組成物 |
JP3964484B2 (ja) * | 1996-10-01 | 2007-08-22 | ワイス株式会社 | ゲルクリーム剤 |
JP2001035458A (ja) * | 1999-07-23 | 2001-02-09 | Sony Corp | 扁平形有機電解液電池 |
-
2003
- 2003-07-22 JP JP2004524120A patent/JP4494202B2/ja not_active Expired - Lifetime
- 2003-07-22 EP EP03741534A patent/EP1541144B8/en not_active Expired - Lifetime
- 2003-07-22 CN CNB038205483A patent/CN100438869C/zh not_active Expired - Fee Related
- 2003-07-22 KR KR1020057001674A patent/KR100996086B1/ko active IP Right Grant
- 2003-07-22 AT AT03741534T patent/ATE485041T1/de not_active IP Right Cessation
- 2003-07-22 AU AU2003281770A patent/AU2003281770A1/en not_active Abandoned
- 2003-07-22 WO PCT/JP2003/009273 patent/WO2004010994A1/ja active Application Filing
- 2003-07-22 ES ES03741534T patent/ES2357229T3/es not_active Expired - Lifetime
- 2003-07-22 DE DE60334630T patent/DE60334630D1/de not_active Expired - Lifetime
- 2003-07-22 PT PT03741534T patent/PT1541144E/pt unknown
- 2003-07-22 US US10/521,958 patent/US7553865B2/en not_active Expired - Fee Related
- 2003-07-25 MY MYPI20032800A patent/MY141808A/en unknown
- 2003-07-28 TW TW092120541A patent/TWI299269B/zh not_active IP Right Cessation
-
2005
- 2005-11-29 HK HK05110853.0A patent/HK1076256A1/xx unknown
-
2010
- 2010-03-15 JP JP2010058017A patent/JP5209653B2/ja not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57126414A (en) | 1981-01-28 | 1982-08-06 | Sumitomo Chem Co Ltd | Ointment |
JPS58185514A (ja) | 1982-04-22 | 1983-10-29 | Hisamitsu Pharmaceut Co Inc | 新規な局所用消炎鎮痛ゲル状クリ−ム剤 |
JPS59227818A (ja) | 1983-06-09 | 1984-12-21 | Mitsubishi Chem Ind Ltd | ゲル状軟膏剤 |
JPS6261918A (ja) * | 1985-09-12 | 1987-03-18 | Sumitomo Pharmaceut Co Ltd | 吸収の良好な外用剤 |
JPH01279831A (ja) | 1988-04-30 | 1989-11-10 | Doujin Iyaku Kako Kk | インドメタシン軟膏剤 |
JPH05271075A (ja) * | 1992-03-26 | 1993-10-19 | Taisho Pharmaceut Co Ltd | 消炎鎮痛クリーム製剤 |
JPH10182458A (ja) * | 1996-12-26 | 1998-07-07 | Taisho Pharmaceut Co Ltd | インドメタシン含有外用剤組成物 |
JP2001354548A (ja) * | 2000-06-09 | 2001-12-25 | Shiseido Co Ltd | 乳化組成物 |
JP2003095985A (ja) * | 2001-09-26 | 2003-04-03 | Lion Corp | 血行促進組成物 |
Also Published As
Publication number | Publication date |
---|---|
ES2357229T3 (es) | 2011-04-20 |
TW200405819A (en) | 2004-04-16 |
EP1541144A4 (en) | 2007-08-08 |
JP4494202B2 (ja) | 2010-06-30 |
MY141808A (en) | 2010-06-30 |
JP2010163454A (ja) | 2010-07-29 |
US7553865B2 (en) | 2009-06-30 |
EP1541144B1 (en) | 2010-10-20 |
KR100996086B1 (ko) | 2010-11-22 |
EP1541144B8 (en) | 2011-09-21 |
EP1541144A1 (en) | 2005-06-15 |
CN1678308A (zh) | 2005-10-05 |
HK1076256A1 (en) | 2006-01-13 |
CN100438869C (zh) | 2008-12-03 |
TWI299269B (en) | 2008-08-01 |
AU2003281770A1 (en) | 2004-02-16 |
KR20050026061A (ko) | 2005-03-14 |
JP5209653B2 (ja) | 2013-06-12 |
DE60334630D1 (de) | 2010-12-02 |
PT1541144E (pt) | 2011-01-24 |
JPWO2004010994A1 (ja) | 2005-11-24 |
US20050239868A1 (en) | 2005-10-27 |
ATE485041T1 (de) | 2010-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101243526B1 (ko) | 마이크로에멀젼 및 서브마이크론 에멀젼 방법 및 조성물 | |
WO1996011002A1 (fr) | Agent anti-inflammatoire a usage externe | |
JP2023547542A (ja) | 円形脱毛症治療用の複方外用製剤及びその製造方法 | |
JPH0820527A (ja) | 角質貯留型抗真菌外用組成物 | |
SA92130087B1 (ar) | تركيب صيدلي محتوي على مركب اللايل أمين | |
JPWO2012033196A1 (ja) | 発泡性エアゾール組成物 | |
TW200409646A (en) | Topical composition | |
JP5209653B2 (ja) | インドメタシン含有ゲルクリーム剤 | |
JP4835411B2 (ja) | アダパレン含有外用剤組成物 | |
JP4313230B2 (ja) | 浴用剤組成物 | |
JP5011118B2 (ja) | インドメタシンを含有する外用液剤 | |
KR20200112919A (ko) | 디클로페낙 함유 유화 겔 조성물 | |
JP5670008B2 (ja) | アダパレン含有外用剤組成物 | |
JPH10139660A (ja) | 水溶性アズレン製剤及びその製造法 | |
JP2003171205A (ja) | ゲル状昆虫忌避製剤 | |
NO315732B1 (no) | Antiinflammatorisk middel til utvortes bruk | |
JPH10139658A (ja) | 皮膚冷却エアゾール剤 | |
JP4774691B2 (ja) | ジメチルイソプロピルアズレン含有外用剤 | |
JPH10101555A (ja) | ゲルクリーム剤 | |
JP2538816B2 (ja) | 動物用ビタミンa製剤 | |
JP2022096993A (ja) | 外用医薬組成物 | |
WO2022131083A1 (ja) | 外用医薬組成物 | |
JP2894843B2 (ja) | 外用抗炎症剤 | |
JPS61209288A (ja) | 冷却用エアゾ−ル組成物 | |
JPH04275215A (ja) | 消炎鎮痛外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004524120 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10521958 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003741534 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500181 Country of ref document: PH Ref document number: 1020057001674 Country of ref document: KR Ref document number: 1020057001588 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020057001588 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200500205 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038205483 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057001674 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003741534 Country of ref document: EP |